Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including astrocytes; strongest in podocytes | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 52 | 0.91 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10842
Sealed predictions
- RAPGEF3 in dopamine neurons, braak-0.45 (p 0.227) → +0.22 (p 0.570)receipt 10850
- RAPGEF3 in astrocytes, braak+0.07 (p 0.849) → +0.52 (p 0.153)receipt 10849
Swarm cases
receipt 10850: RAPGEF3 in dopamine neurons, braak
- power
- full sample -0.19 (p 0.444, n 18), 95% CI -0.60 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.671, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.671, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.11, sign flips 0; without severely affected donors -0.19 (p 0.444, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.67 (p 0.0022, n 18) vs -0.19 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAPGEF3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RAPGEF3 · oligodendrocytes · braak: substantia nigra, an independent cohort (already registered)
receipt 10849: RAPGEF3 in astrocytes, braak
- power
- full sample +0.21 (p 0.398, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.25 (p 0.319, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.19 (p 0.455, n 18). could be the mix.
- skeptic
- leave-one-out range +0.12 to +0.37, sign flips 0; without severely affected donors +0.21 (p 0.398, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.67 (p 0.0022, n 18) vs +0.21 in astrocytes. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAPGEF3 in astrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RAPGEF3 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.15 p 0.594 (needs p < 2.0e-4)
Receipts
loading the receipts